Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely.
Bioventus has raised $400.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in July 2025.
Bioventus's investors include Wells Fargo, Ampersand Capital Partners, Alcentra Capital Corporation.
Bioventus is headquartered in Durham, United States.
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely.
Bioventus is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Bioventus — Funding & Investors." VCBacked, July 31, 2025, https://www.vcbacked.co/company/bioventus. Accessed September 30, 2026.
VCBacked. (2025). Bioventus — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/bioventus
{{cite web |title=Bioventus — Funding & Investors |url=https://www.vcbacked.co/company/bioventus |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated